Integrated Advisors Network LLC grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 12.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 16,261 shares of the biotechnology company’s stock after purchasing an additional 1,754 shares during the quarter. Integrated Advisors Network LLC’s holdings in Exelixis were worth $261,000 as of its most recent filing with the SEC.
Several other hedge funds also recently made changes to their positions in the company. Signaturefd LLC grew its holdings in shares of Exelixis by 28.8% during the fourth quarter. Signaturefd LLC now owns 2,767 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 619 shares during the last quarter. CWM LLC grew its holdings in shares of Exelixis by 12.8% during the third quarter. CWM LLC now owns 6,053 shares of the biotechnology company’s stock worth $95,000 after buying an additional 687 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Exelixis by 5.6% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 13,253 shares of the biotechnology company’s stock worth $208,000 after buying an additional 703 shares during the last quarter. US Bancorp DE grew its holdings in shares of Exelixis by 1.1% during the third quarter. US Bancorp DE now owns 75,522 shares of the biotechnology company’s stock worth $1,184,000 after buying an additional 786 shares during the last quarter. Finally, Louisiana State Employees Retirement System grew its holdings in shares of Exelixis by 0.9% during the fourth quarter. Louisiana State Employees Retirement System now owns 86,400 shares of the biotechnology company’s stock worth $1,386,000 after buying an additional 800 shares during the last quarter. Hedge funds and other institutional investors own 84.74% of the company’s stock.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on the company. Piper Sandler reissued an “overweight” rating and set a $32.00 price target on shares of Exelixis in a report on Wednesday, February 8th. Credit Suisse Group started coverage on shares of Exelixis in a research report on Thursday, January 26th. They issued an “outperform” rating and a $29.00 price objective for the company. Morgan Stanley reduced their price objective on shares of Exelixis from $22.00 to $21.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 12th. StockNews.com upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, April 14th. Finally, JMP Securities reduced their price objective on shares of Exelixis from $25.00 to $24.00 and set a “market outperform” rating for the company in a research report on Thursday, January 19th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.92.
Exelixis Trading Up 0.5 %
Exelixis (NASDAQ:EXEL – Get Rating) last issued its quarterly earnings data on Tuesday, February 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). Exelixis had a return on equity of 7.54% and a net margin of 11.31%. The business had revenue of $423.92 million for the quarter, compared to analysts’ expectations of $418.71 million. During the same period last year, the business earned $0.29 earnings per share. The company’s revenue for the quarter was down 6.0% on a year-over-year basis. Sell-side analysts forecast that Exelixis, Inc. will post 0.67 earnings per share for the current fiscal year.
Insider Transactions at Exelixis
In other news, Director Carl B. Feldbaum sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 9th. The shares were sold at an average price of $17.78, for a total transaction of $711,200.00. Following the completion of the transaction, the director now directly owns 18,701 shares of the company’s stock, valued at approximately $332,503.78. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Exelixis news, EVP Jeffrey Hessekiel sold 77,860 shares of Exelixis stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $17.13, for a total value of $1,333,741.80. Following the completion of the sale, the executive vice president now directly owns 527,716 shares of the company’s stock, valued at approximately $9,039,775.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Carl B. Feldbaum sold 40,000 shares of Exelixis stock in a transaction that occurred on Thursday, February 9th. The stock was sold at an average price of $17.78, for a total transaction of $711,200.00. Following the completion of the sale, the director now directly owns 18,701 shares of the company’s stock, valued at $332,503.78. The disclosure for this sale can be found here. Insiders sold a total of 237,100 shares of company stock valued at $4,212,089 in the last ninety days. Corporate insiders own 2.90% of the company’s stock.
Exelixis Profile
Exelixis, Inc operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Read More
- Get a free copy of the StockNews.com research report on Exelixis (EXEL)
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation’s Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Get Rating).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
